ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1431

Izokibep, a Unique IL-17A Inhibitor, Improves Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis up to Week 46 – Phase 2 RCT Results

Peter C. Taylor1, Kurt de Vlam2, Philip J. Mease3, Paul M. Peloso4, Dieter Wetzel5, Apinya Lertratanakul6, Nikolai Brun7, Brian Wiens8, Jan Brandt-Juergens9, Edit Drescher10, Eva Dokoupilova11, Anna Rowińska-Osuch12, Nadia Abdel-Kader Martin13 and Frank Behrens14, 1Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 2University Hospitals Leuven, Leuven, Belgium, 3Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, 4ACELYRIN, INC., Naples, FL, 5toclinco GmbH, Freiburg im Breisgau, Germany, 6ACELYRIN, Chicago, IL, 7Affibody AB, Solna, Sweden, 8ACELYRIN, Inc., Half Moon Bay, CA, 9rheumatologische Schwerpunktpraxis, Berlin, Germany, 10Csolnoky Ferenc Hospital / Vital Medical Center Private Clinci, Veszprém, Hungary, 11Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology; MEDICAL PLUS sro, Brno, Czech Republic, 12ETG Warszawa, Warsaw, Poland, 13Hospital Quironsalud Infanta Luisa, Sevilla, Spain, 14Goethe University, Division of Rheumatology, University Hospital and Fraunhofer Institute for Translational Medicine & Pharmacology, Frankfurt, Germany

Meeting: ACR Convergence 2023

Keywords: Biologicals, Disease Activity, Outcome measures, Psoriatic arthritis, Randomized Trial

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1412–1441) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II: SpA

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Izokibep is a novel small protein IL-17A inhibitor, unique for its high IL-17A binding affinity, a small size at 18.6 kD and albumin binding site enabling access in inflamed tissues and two-week half-life. IL-17A is key in psoriatic arthritis (PsA) pathogenesis and its inhibition is known to improve quality of life. Here, we report results of izokibep treatment to week 46 on patient-reported outcomes (PROs), following a 16-week placebo-controlled period1. PRO endpoints include PsAID-9, HAQ-DI, TSQM-9, and patient reported pain, itch, and global disease activity.

Methods: Izokibep doses of 80 mg Q2W or 40 mg Q2W were evaluated to 46 weeks or study termination. The original placebo arm continued to 16 weeks, then switched to 80 mg Q2W in a multicenter trial (NCT04713072). This study was terminated once 16-week results were available to continue to explore the effective dose range in a next P2b/3 trial. The results include as observed analysis evaluating change from baseline to weeks 16, 32 and 46. Patients met CASPAR criteria and had ≥3 swollen (SJC) and ≥3 tender joints (TJC) on a 66/68 joint count and inadequate response to previous NSAIDs, csDMARDs, or TNF inhibitor therapy.

Results: 135 patients were randomized 1:1:1 to izokibep 40 mg, 80 mg or placebo to week 16 when placebo transitioned to 80 mg Q2W. Patients had a mean age of 49 (SD 12) years, a mean BMI of 29 (5) kg/m2, a mean PsA disease duration of 7 (8) years, a mean SJC of 10 (7) and TJC of 17 (10). At week 32, 96 of 102 eligible patients had evaluable data and at week 46, 59 of 62 eligible patients had evaluable data with similar distribution across groups. Clinically important improvements were evident for pain, patient global disease activity, itch, PsAID-9, treatment satisfaction on the TSQM-9 for those starting on 80 mg at baseline as well as those switching to 80 mg at week 16. The 80 mg dose showed improvements from week 16 to 46, whereas the 40 mg dose was largely stable (Figure 1). Consistent improvements across all PsAID-9 subdomains were evident for the 80 mg doses at week 32 and week 46 (Figure 2). Pain responders, defined as achieving patient reported pain < 30/100, improved from weeks 16 to 32 and 46 for those starting with 80 mg and those switching to 80 mg at week 16 while the 40 mg dose remained largely stable (Figure 3). From week 16 to week 46, the most frequently reported adverse events were injection site reactions, injection site erythema and nasopharyngitis which were distributed similarly across groups. One patient dropped out for ISR over this interval. There were no dose-related infection risks.

Conclusion: Izokibep led to continuing improvements across all PROs from baseline to weeks 16, 32 and 46 with greater improvements in the 80 mg dose groups. The GRAPPA validated PsAID-9 showed clinically important improvements in patient reported quality of life across all subdomains over weeks 16, 32 and 46. More than 70% of patients achieved marked pain control. Izokibep was generally well tolerated with no new safety issues to week 46.

References
1Taylor, P C et al. ACR 2022. Abstract 0199. Arthritis Rheumatol. 2022; 74 (suppl 9).

Supporting image 1

Figure 1. Continued Improvements in Multiple Patient-Reported Outcomes from Baseline to Weeks 16, 32 and 46

Supporting image 2

Figure 2. Continued Improvement in the GRAPPA Validated PsAID Quality of Life Index over Weeks 16, 32, 46

Supporting image 3

Figure 3. Patient Reported Pain Responders with Pain <30/100 at Weeks 16, 32 and 46


Disclosures: P. Taylor: AbbVie, 2, Biogen, 2, Eli Lilly, 2, Fresenius, 2, Galapagos, 2, 5, Gilead Sciences, 2, GSK, 2, Janssen, 2, Nordic Pharma, 2, Pfizer Inc, 2, Sanofi, 2, UCB, 2; K. de Vlam: AbbVie, 2, Amgen, 2, Celgene, 2, 5, 6, Eli Lilly, 2, 6, Galapagos, 2, 5, 6, Novartis, 2, 6, UCB, 2, 6; P. Mease: AbbVie, 2, 5, 6, Acelyrin, 2, Aclaris, 2, Amgen, 2, 5, 6, Boehringer Ingelheim, 2, Bristol Myers Squibb, 2, 5, Eli Lilly, 2, 5, 6, Galapagos, 2, Gilead, 2, GlaxoSmithKline, 2, Inmagene, 2, Janssen, 2, 5, 6, MoonLake Pharma, 2, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, Sun Pharma, 2, 5, UCB Pharma, 2, 5, 6, Ventyx, 2, Xinthera, 2; P. Peloso: ACELYRIN, 3, 8, 11; D. Wetzel: ACELYRIN, 2, Affibody, 2; A. Lertratanakul: AbbVie, 11, ACELYRIN, 3, 11; N. Brun: Affibody, 3, 8, 11; B. Wiens: ACELYRIN, 3, 8, 11, Horizon Therapeutics, 8; J. Brandt-Juergens: AbbVie/Abbott, 2, 6, Affibody, 2, Bristol-Myers Squibb(BMS), 2, 6, Eli Lilly, 2, 6, Gilead, 2, Janssen, 2, 6, Medac, 2, 6, Merck/MSD, 2, 6, Novartis, 2, 6, Pfizer, 2, 6, Roche, 2, 6, Sanofi-Aventis, 2, 6, UCB, 2, 6; E. Drescher: None; E. Dokoupilova: AbbVie/Abbott, 5, Eli Lilly, 5, Galapagos NV, 5, Gilead, 5, GlaxoSmithKlein(GSK), 5, Hexal, 5, Janssen, 5, Novartis, 5, Pfizer, 5, Samsung Bioepis, 5, Sanofi, 5, UCB, 5; A. Rowińska-Osuch: None; N. Abdel-Kader Martin: None; F. Behrens: AbbVie, 2, 6, Affibody, 2, Amgen, 6, Boehringer-Ingelheim, 2, Celgene, 5, Chugai, 5, Eli Lilly, 6, Genzyme, 6, Gilead Sciences, 2, GSK, 2, 6, Janssen, 2, 5, MoonLake, 2, 6, MSD, 2, 6, Novartis, 6, Pfizer, 2, 5, 6, Roche, 5, Sandoz, 2, 6, Sanofi, 2, 6.

To cite this abstract in AMA style:

Taylor P, de Vlam K, Mease P, Peloso P, Wetzel D, Lertratanakul A, Brun N, Wiens B, Brandt-Juergens J, Drescher E, Dokoupilova E, Rowińska-Osuch A, Abdel-Kader Martin N, Behrens F. Izokibep, a Unique IL-17A Inhibitor, Improves Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis up to Week 46 – Phase 2 RCT Results [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/izokibep-a-unique-il-17a-inhibitor-improves-patient-reported-outcomes-in-patients-with-active-psoriatic-arthritis-up-to-week-46-phase-2-rct-results/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/izokibep-a-unique-il-17a-inhibitor-improves-patient-reported-outcomes-in-patients-with-active-psoriatic-arthritis-up-to-week-46-phase-2-rct-results/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology